Family Preservation Services, Inc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 465 Truman Hill Rd, Hardy, VA 24101 Phone: 540-483-0312 Fax: 540-483-0343 |
Principled Behavior Consultants Llc Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 640 Old Ridge Dr, Hardy, VA 24101 Phone: 510-205-2890 |
Brags Consulting Llc Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 1609 Coopers Cove Rd, Hardy, VA 24101 Phone: 505-319-8123 |
News Archive
The non-profit MedicAlert Foundation published a "Code of Conduct" in an effort to help consumers evaluate the integrity of organizations providing emergency medical information and identification services. In addition, as part of the "Code of Conduct" the Foundation has established business practice standards for medical information and identification service organizations that house consumer health information. Across the country millions of consumers are using personal health records, emergency medical information services, personal medical alarms systems or medical identification jewelry services.
A study of diabetes in overweight and obese youngsters bears an ominous warning about future health care trends in this country. It found that Type 2 diabetes, a new scourge among young people, progresses faster and is harder to treat in youngsters than in adults. ... Congressional Republicans, meanwhile, are bent on dismantling health care reforms that could greatly assist in curbing the obesity epidemic.
The introduction of pneumococcal vaccines for treating otitis media in children has not prevented complications from occurring, according to new research presented at the 2009 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, in San Diego, CA. In fact, the research suggests that the focus has changed on what complications may arise.
Teva Pharmaceutical Industries Ltd. today announced positive top-line results from the GALA (Glatiramer Acetate Low-Frequency Administration) Phase III clinical trial assessing the efficacy, safety and tolerability of 40 mg/1 ml glatiramer acetate injection (GA) administered subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis (RRMS) patients.
› Verified 6 days ago